Clinical Research Details
Title:
A Multicenter Phase II Study Incorporating Doxil and Rituximab into the Magrath Regimen for HIV-Negative and HIV-Positive Patients with Newly Diagnosed Burkitt’s and Burkitt-like Lymphoma
Purpose:
The primary objective of this study is to evaluate the response rate for patients with Burkitt’s and Burkitt-like lymphoma
Study Number:
109468
Number of Patients:
25
Elgibility:
Adults (> 18) with biopsy proven newly diagnosed Burkitt’s lymphoma or Burkitt-like lymphoma.
Treatment:
This study involves treatment with a chemotherapy known as the Magrath regimen. This study will evaluate the addition of either the anti-cancer drug rituximab or the anti-cancer drug doxil added to the standard chemotherapy treatment called the Magrath regimen.
Principal Investigator:
Enrollment Phone:
(708) 327-3223